vTv Therapeutics (VTVT) Stock Price, News & Analysis

Company Overview

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease. In parallel, vTv is advancing TTP399, a liver-selective glucokinase activator designed as an adjunctive therapy for type 1 diabetes. These programs exemplify vTv’s strategy of targeting high-need indications with differentiated oral therapies.

Since its inception, vTv Therapeutics has pursued strategic collaborations and licensing agreements to support its clinical development efforts and potential commercialization. While primarily operating in the United States, the company actively seeks global partnerships to extend the reach of its pipeline. Led by a management team with extensive experience in pharmaceutical research, clinical development and regulatory affairs, vTv remains committed to progressing its candidates through pivotal trials toward regulatory approval.

Key Stats

• Today's Range: $20.00 to $21.40
• 50-Day Range: $14.11 to $20.48
• 52-Week Range: $12.62 to $26.99
• Volume: 5,615 shs
• Average Volume: 2,984 shs
• Market Capitalization: $66.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.50
• Consensus Rating: Buy

vTv Therapeutics Stock Analysis - MarketRank™

vTv Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 521st out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

vTv Therapeutics has a consensus price target of $35.50, representing about 69.0% upside from its current price of $21.00.

Amount of Analyst Coverage

vTv Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of vTv Therapeutics is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of vTv Therapeutics is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

vTv Therapeutics has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.99% of the float of vTv Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

vTv Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in vTv Therapeutics has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

vTv Therapeutics does not currently pay a dividend.

Dividend Growth

vTv Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.99% of the float of vTv Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

vTv Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in vTv Therapeutics has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

vTv Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for vTv Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.20% of the stock of vTv Therapeutics is held by insiders.

Percentage Held by Institutions

Only 17.51% of the stock of vTv Therapeutics is held by institutions.

VTVT Stock Analysis - Frequently Asked Questions

How have VTVT shares performed this year?

vTv Therapeutics' stock was trading at $13.81 at the start of the year. Since then, VTVT shares have increased by 52.1% and is now trading at $21.00.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) released its quarterly earnings results on Tuesday, August, 12th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.07.

When did vTv Therapeutics' stock split?

Shares of vTv Therapeutics reverse split before market open on Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did vTv Therapeutics IPO?

vTv Therapeutics (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), NIO (NIO), VBI Vaccines (VBIV), Vaxart (VXRT) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTVT
• CIK: 1641489
• Web: www.vtvtherapeutics.com
• Phone: (336) 841-0300
• Fax: 336-841-0310
• Employees: 9
• Year Founded: 1998

Price Target and Rating

• Average Price Target for vTv Therapeutics: $35.50
• High Price Target: $36.00
• Low Price Target: $35.00
• Potential Upside/Downside: +71.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.46 million
• Net Margins: N/A
• Pretax Margin: -140,435.28%
• Return on Equity: -179.75%
• Return on Assets: -55.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.98
• Quick Ratio: 4.98

Sales & Book Value

• Annual Sales: $17 thousand
• Price / Sales: 3,896.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.48 per share
• Price / Book: 4.63

Miscellaneous

• Outstanding Shares: 3,195,000
• Free Float: 3,152,000
• Market Cap: $66.23 million
• Optionable: Not Optionable
• Beta: 0.64